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CONSIDERATIONS OF ANTIBIOTIC TREATMENT
Abstract
Genital Ureaplasma is a worldwide issue in obstetrics and gynecology. Morbidities
can include pelvic inflammatory disease, infertility, miscarriage, preterm delivery, and
chorioamnionitis, if left untreated. The quality improvement (QI) initiative used a
retrospective chart review of 128 subjects, collecting data of antibiotic treatment differences
and recurrence of genital Ureaplasma at a corporate owned obstetrical and gynecologic
outpatient clinic in the metro-Denver area. The investigator used the percentage change
mathematical formula to determine the percentage difference between patient antibiotic
treatment only with symptomatic genital Ureasplasma versus antibiotic treatment of the
patient and the partner. Overall, the project did not show statistical difference between the
two variables (percentage change of 14.47%). However, unintentional findings were reported
on the recurrence difference between patient and patient and partner treatment between the
antibiotics doxycycline (20.7% and 16.57%), azithromycin (50.07% and 50.7%), and
clindamycin (100% recurrence rate with and without partner treatment). The major limitation
of this project was the small sample size. The most significant implication of this project was
that the antibiotic findings were consistent with CDC and UpToDate guidelines. It appeared
that doxycycline has a higher success rate for treatment of genital Ureaplasma. Further
investigation is recommended.
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Considerations of Antibiotic Treatment for Genital Ureaplasma
Executive Summary
Problem
Symptomatic genital Ureaplasma is an emerging concern in gynecology. With potential risks
of untreated symptomatic genital Ureaplasma including pelvic inflammatory disease,
infertility, miscarriage, preterm delivery, and chorioamnionitis, it is imperative that provider
education with a review of CDC guidelines are explored starting at the clinical level. The
PICO statement the project sought to address was whether women with symptomatic genital
Ureaplasma have a decreased incidence of symptomatic recurrence when both the patient
and the partner are treated with antibiotic therapy than treatment of the patient alone.
Purpose
This capstone project which was a quality improvement (QI) initiative, investigated if there
was a difference in the incidence of symptomatic recurrence of genital Ureaplasma in the
female patient when treating the patient and partner as compared to treating the patient alone
with antibiotic therapy.
Goals
The primary goal of the project was to determine whether the relationship between antibiotic
treatment differences and recurrence of symptomatic genital Ureaplasma was statistically
significant. A secondary goal was to explore the recommendations of evidenced-based
guidelines related to urethritis and cervicitis caused by Ureaplasm
Objective
The objective of this quality improvement initiative was to conduct a retrospective chart
review of the antibiotic treatment differences of patient and partner treatment versus patient
only treatment for genital Ureaplasma within a corporate owned obstetrics and gynecology
office in the metro-Denver area
Plan
In planning the project, a data collection tool was created and approved by the QI project site
administrator to identify the diagnosis for the visit using ICD-10 codes as identifiers, positive
PCR testing for genital Ureaplasma, antibiotic treatment (doxycycline, azithromycin, or
other), partner treatment, test of cure results, and recurrence of symptoms resulting in a return
visit in a 3-month period of time. A priori sampling size of 128 was calculated using the
G*Power software (Department of Psychology, 2019) with the alpha of 0.05 and power of
0.80. The investigator used a percentage change mathematical formula to determine the
percentage difference between the two scores. The inferential statistic used was Kendall’s
tau.
Outcomes and Results
The project did not show statistical difference between the two variables (percentage change
of 14.47%). However, unintentional findings were reported on the recurrence difference
between patient and patient and partner treatment between the antibiotics doxycycline (20.7%
and 16.57%), azithromycin (50.07% and 50.7%), and clindamycin (100% recurrence rate
with and without partner treatment). The unintentional findings are consistent with CDC and
UpToDate guidelines. It appeared that doxycycline has a higher success rate for treatment of
genital Ureaplasma.
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Considerations of Antibiotic Treatment for Genital Ureaplasma
Symptomatic genital Ureaplasma is a world-wide issue in obstetrics and gynecology.
A single study performed at a multicenter/multicultural laboratory concluded 47.3% (n=833)
of the female participants sampled tested positive for genital Ureaplasma when the patient
presented with clinical symptoms of vaginitis (Leli, et al., 2018). This exposure rate is
consistent with other studies. With potential risks of untreated symptomatic genital
Ureaplasma including pelvic inflammatory disease, infertility, miscarriage, preterm delivery,
and chorioamnionitis, it is imperative that education starting at the clinical level is explored.
This quality improvement (QI) initiative was a retrospective chart review of the antibiotic
treatment differences and recurrence of genital Ureaplasma at a corporate owned obstetrical
and gynecologic outpatient clinic in the metro-Denver area. This paper includes a description
of the practice problem with an articulated review of supporting literature and evidenced
based practice guidelines. The paper also presents a market/risk analysis for conducting the
project, the project objectives and methodology and evaluation plan, as well as an analysis of
project findings and results and a discussion of limitations, recommendations and
implications for change.
Problem Recognition and Definition
Project Purpose
The purpose of this capstone project, which is a quality improvement (QI) initiative,
was to investigate if there is a statistical difference in the incidence of symptomatic
recurrence of genital Ureaplasmas in the female patient when treating the patient and partner
as compared to treating the patient alone with antibiotic therapy. The primary investigator
used a retrospective chart review to identify symptoms of genital Ureaplasma and antibiotic
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treatment, to determine if the female patient alone or the patient and partner were treated for
Ureaplasma, and measured rates of symptomatic recurrence of genital Ureaplasma in the
intervention and the comparison groups.
Problem Statement
The problem statement for the proposed project was as follows: Lack of treatment of
partners who test positive for Ureaplasma may increase sexual transmission of this
microorganism. The problem statement for the capstone project was identified when the
primary investigator recognized the antibiotic treatment differences, in women with positive
Ureaplasma culture, between 13 providers in an obstetric and gynecologic clinic in the metroDenver area. The primary investigator suspected that treatment inconsistencies among
providers were due to the lack of knowledge of genital Ureaplasma signs, symptoms, and
negative effects, as well as preferred antibiotic treatment options. The primary investigator
and another seasoned nurse practitioner became concerned with the number of female
patients that returned to the clinic with recurrent symptoms of genital Ureaplasma.
The risks of genital Ureaplasma if left untreated in symptomatic patients, is known to
lead to pelvic inflammatory disease (PID), ectopic pregnancy, infertility by blocking
fallopian tubes, and recurrent vaginosis in the non-pregnant female. In a pregnant patient,
Ureaplasma can lead to preterm rupture of membranes and preterm labor/delivery (Diaz, et
al., 2013).
The Center for Disease Control (2015) guidelines recommend antibiotic treatment for
male urethritis and female cervicitis. Genital Ureaplasma falls into this category. With the
aforementioned risk of genital Ureaplasma, it is important for clinicians to provide antibiotic
treatment in a timely manner.
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PICO
The capstone project utilized the “PICO” question format rather than a formal
research hypothesis. The PICO acronym stands for: Population or Patient (P), Intervention
(I), Comparative Intervention (C), and Outcome (O) (Houser & Oman, 2011). The question
the project sought to address was: Do women with symptomatic genital Ureaplasmas have a
decreased incidence of symptomatic recurrence when both the patient and the partner are
treated with antibiotic therapy than treatment of the patient alone?
In the PICO format, the question reads:
P (patient): Women with symptomatic genital Ureaplasmas
I (Intervention): Treating patient and partner with antibiotic therapy
C (comparison): Treating the patient alone
O (outcome): Decrease the incidence of symptomatic recurrence
Project Significance, Scope, and Rationale
Genital Ureaplasma species have gained more attention as being an attributing
bacterium associated with adverse effects to the health of men, women, and neonates. In
women, genital Ureaplasma can cause pelvic inflammatory disease (PID), leading to potential
ectopic pregnancy or infertility. According to the CDC (2017), an estimated 2.5 million
women aged 18–44 years in the United States reported a history of PID diagnosis within their
lifetime. This quality improvement project may have a financial impact by decreasing the rate
of PID seen in a clinical setting, as well as decreasing cost of potential adverse effects from
the Ureaplasma species.
The scope of this project was a quality improvement project internal to a large
obstetrics and gynecology clinic in the metropolitan Denver area. This study was not meant
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to develop new knowledge or to be generalized outside of the agency where the QI project
took place.
The rationale for the project was to inform providers within the practice of antibiotic
treatment for genital Ureaplasma. The investigator identified the capstone project with DNP
Essential II: Organizational and Systems Leadership for Quality Improvement and Systems
Thinking (AACN, 2006). This project focused on the direct care of patients who had
symptomatic Ureaplasma and their partners. It provided the investigator with an opportunity
to apply evidence-based guidelines/policies that could potentially improve the quality of
health care for this population.
Foundational Theory
The investigator used two theories for the theoretical framework for the capstone
project, which were the Neuman Systems Model and Lewin’s Theory of Change.
Betty Neuman (1924-2008), introduced her Neuman Systems Model in 1970 while
she was a professor at UCLA. Her background in nursing included Community and Mental
Public Health. “The goal of the model was to provide a holistic overview of the
physiological, psychological, sociocultural, and developmental aspects of human beings”
(“Betty Neuman”, 2010). The theory developed over time with adaptability for use in the
classroom, community, and clinical practice. The purpose of the Neuman Systems Model is
viewing the patient, or client as termed by Dr. Neuman in her theory, as an open system that
reacts to stressors. Stressors may include environmental, psychological, developmental,
physiological, and spiritual sources.
One of the major concepts of the model was identifying the client as having “rings”
representing each component of the model. The inner “ring” is the central circle, which is the
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basic vital signs, genetics, strengths and weakness of the system (client). The next ring is the
line of resistance. This protects the client from outside factors/stressors and maintains a
healthy system. The next ring is the flexible line of defense, which serves as a protective
buffer to prevent stressors from invading the client (Ume-Nwagbo et al., 2006). This line is
seen as being fluid and can move away or towards the line of resistance. The normal line of
defense completes the Neuman Systems Model and is thought to be developed over time as
the system learns coping mechanisms, as well as outside influences and beliefs.
The Neuman Systems model is a middle-range theory that can be applied to the
Capstone problem statement: As a nurse or provider, their function is to assess an
individual’s reaction to a stressor (as in this case, symptoms consistent with genital
Ureaplasma) has on the system (or the patient). The primary care provider can use primary
(education), secondary or preventative measures (antibiotic treatment to patient and partner),
and tertiary measures (management/treatment of recurrent symptoms) to return the client to
health and stability. See Appendix A for The Neuman Systems Model.
Kurt Lewin (1890-1947) was a German-American social psychologist. Lewin’s
Change Theory consists of three levels: unfreezing, changing/transition, and refreezing. The
unfreezing stage begins after the problem or the needs for change is identified. In unfreezing,
“physicians and staff must be motivated to change by means of exposure to new ideas and
creating a sense of urgency around the shared vision of how patient care outcomes and the
work environment could be enhanced by the proposed change” (Stichler, 2011, p. 9). During
the unfreezing stage, in this case, providers must be prepared for change by treatment of
patient and partner in light of positive Ureaplasma. The transition or moving phase consists
of a plan of action that is developed to engage “people to try out the proposed change”
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(Shirey, 2013, p. 70). The last phase, the refreezing stage, consists of acceptance of change
into routine practice. Lewin’s model is found to be versatile, simple to implement, and easy
to understand (Shirey, 2013).
Applying Lewin’s Change Theory in context with the problem statement, the problem
was identified within one OB/Gyn practice where providers are treating women with positive
genital Ureaplasma inconsistently. Patients returning to the clinic with recurrent symptoms of
genital Ureaplasma promoted the Unfreezing phase. The Transition phase may evolve over
time during the Capstone project, depending on the results of the study and recommendations
made by this investigator. Refreezing or acceptance of a different way of treating the patient
and partner may occur if the results point to a change in routine practice of managing
Ureaplasma infections (see Appendix B for Lewin’s Theory of Change model).
Literature Selection/Systematic Process
A systematic review of the literature was conducted using CINAHL, Google Scholar,
PubMed, Ovid, and Sage databases between the dates of September 2018 through September
2019. The search was limited to articles dated after 2009 and publications in English
language, but were from several countries including Italy, India, Brazil, Switzerland, and the
United States. Exclusion criteria included articles more than 7 years old, written in language
other than English, focus on pregnancy, and pediatrics. Keywords for the literature review
included: Genital Ureaplasma, Ureaplasma parvum, Ureaplasma urealyticum, real-time PCR,
antibiotic susceptibility, vaginal discharge, Mycoplasmas, asymptomatic infection, NGU,
cervicitis, urethritis, diagnosis, management, and partner treatment. By using a combination
of the keywords, the investigator found 50 articles that was later narrowed to 30 articles
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for Disease Control and Prevention as well as UpToDate.
Scope of Evidence
There were several types of studies used in the literature, including: quasiexperimental, systematic review, retrospective analysis, experimental, and correlational.
Melnyk and Fineout-Overhalt’s (2015) table was used to identify the level of evidence using
four of seven levels for the 30 articles and are identified as follows:
•

Level I- systematic review or meta-analysis of randomized control trials- 11 articles,

•

Level II- evidence from one or more randomized control trials- 3 articles,

•

Level III- controlled trial with no randomization- 12 articles, and

•

Level IV- case controlled or cohort studies- 4 articles.

Background of Problem
Ureaplasma is considered a normal flora residing in the respiratory and urogenital
tract of humans. According to Saigal, Dhawan, Rawre, Khanna, and Chaundry (2016),
approximately 60-80% of sexually active women have been exposed to genital Ureaplasma
before they are 40 years old, and remain asymptomatic in both developed and developing
countries. Symptomatic Ureaplasma are bacteria known to cause adverse effects in men,
women, and neonates.
Combaz-Sochnchen and Kuhn (2017) found limited literature regarding women and
urogenital Ureaplasma. The authors noted women experiencing chronic urinary tract
symptoms, including urethritis, overactive bladder, and interstitial cystitis, should be tested
by PCR assay for Ureaplasma spp.

7
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After the investigator conducted a search for applicable research articles related to the
PICO question, a systematic review of evidence table was created (see Appendix C for an
example). Emerging themes from the search resulted in five categories: biology and
transmission of genital Ureaplasmas, urethritis and cervicitis, microbiology of diagnosis and
detection, antibiotic susceptibility, and clinical guidelines.
Review of Evidence
Systematic Review of the Literature
Biology and transmission of genital Ureaplasmas. Genital Ureaplasma belong in
the smallest, free-living self-replicating organisms of Mollicutes, and can also be found in the
general category of genital Mycoplasmas (Kokkoyail & Dhawan, 2015). There are two
known genital biovars, those being Ureaplasma urealyticum (Biovar 1) and Ureaplasma
parvum (Biovar 2). Together, these biovars identified under the category of Ureaplasma
species (spp.). For the purpose of the project, the investigator did not differentiate findings
into the two biovars, but as Ureaplasma species.
Ureaplasma spp. is transmitted by direct host contact including genital to genital,
genital to oral, as well as vertical transmission (mother to fetus), or by transplanted tissue
(Waites & Bronze, 2019). Genital Ureaplasma is not considered a sexually transmitted
infection since it is found as a normal flora in humans.
In transmission from male to female partner, men “act as asymptomatic carriers and
function as reservoirs and vectors" (Silva, Cerqueira, Teixeira, Bicho, Campainha, Amorin, &
Medeiros, 2018, p. 1003). Ureaplasma pathogens may be introduced into a healthy vagina
through intercourse causing lysis of healthy Lactobacillus.
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Neonates who are colonized with Ureaplasma are presumably exposed during a
vaginal delivery, since colonization is less common in infants born via cesarean section
(Baum, 2018). In this case, Mycoplasmas (Mycoplasma and Ureaplasma spp.) adhere to
mucosal epithelial cells of the respiratory tract. It can disseminate to other sites when there is
a disruption of the mucosa or an underlying immunity of the host, in this instance, the
neonate (Baum, 2018).
Urethritis and cervicitis. Symptoms of urethritis or cervicitis are what often prompts
the patient to seek medical care. Clinical complaints for women are abnormal vaginal
discharge, pelvic pain, vaginal burning, dyspareunia, and abnormal uterine bleeding (Centers
for Disease Control and Prevention, 2015). The CDC (2015) defines the symptoms of males
and females as experiencing dysuria, urethral pruritus, and mucoid, mucopurulent, or
purulent discharge.
Co-infections can be seen in the presence of genital Ureaplasma. Ureaplasma will
thrive in a favorable pH environment, with better survival rate in the symbiotic relationship
with anaerobic bacterial vaginosis (Rumyantseva, et al., 2018). Frolund et al. (2019) found
bacterial vaginosis is often present in Ureaplasma positive samples speculating that
production of urea from Ureaplasma increases vaginal pH, which in turn leads to an increased
bacterial load of bacterial vaginosis.
The prevalence of genital Ureaplasma spp. suggest sexually active adults should be
screened for these pathogens and condoms should be promoted. "Though coinfections were
not associated with increase in severity of clinical manifestations, however, these infections
could be transmitted to their partners contributing to clinical morbidity" (Saiga, Dhawan,
Rawre, Khanna, Chaudhry, 2016, p. 195). If left untreated, symptomatic Ureaplasma spp. are

CONSIDERATIONS OF ANTIBIOTIC TREATMENT

10

associated with pelvic inflammatory disease (PID) and infertility. Obstetric complications
include chorioamnionitis, spontaneous abortion/miscarriage, stillbirth, and premature rupture
of membranes (Verteramo, Patella, Calzolari, Recine, Marcone, Osborn, & Degener, 2013).
Microbiology of diagnosis and detection. The incubation period of genital
Ureaplasmas is approximately 10-20 days (Kimberlin, Brady, & Jackson, 2018).
Symptomatic genital Ureaplasma on exam and microscopically may include mucopurulent
discharge, first void urine with >10 WBC's on high power field of microscopic assessment,
and gram staining of >2WBC's per oil immersion field. Symptomatic cervicitis characteristics
include a purulent or mucopurulent discharge visible to the examiner in the endocervical
canal or on an endocervical swab specimen and a friable cervix or bleeding of the endocervix
when touched with a cervical swab (Liu, Cao, Zhao, Zhao, & Huang, 2014).
Since Mollicutes lack a cell wall, the organism cannot be visualized by Gram stain.
Nucleic-acid amplification tests (NAAT), including PCR and DNA chip assay, are used for
detection of Mycoplasmas (Baum, 2018). Polymerase chain reaction (PCR) is the test of
choice when testing for Ureaplasma due to affordability and timeliness of results. PCR
testing is collected from the urethra or endocervix with a polyester or nylon tipped swab,
which is then placed in the liquid transport material for laboratory assessment.
Antibiotic susceptibility. Four classes of antibiotics are recognized for treatment of
urogenital Ureaplasma: fluoroquinolones, tetracycline, chloramphenicol, and macrolide
classes (Beeton, & Spiller, 2016). Based on CDC (2015) guidelines, the first-line treatment is
azithromycin 1gram or doxycycline 100mg/day for 7 days. In the United States, doxycycline
is available with high antibiotic susceptibility rate at 76%, whereas ciprofloxacin showed
resistance to Ureaplasma at 82% (Kasprzykowska, et al., 2017). Other susceptible antibiotics

CONSIDERATIONS OF ANTIBIOTIC TREATMENT

11

to Ureaplasma available in the U.S. are minocycline with 74.7% susceptibility and
clindamycin with 74% susceptibility. Diaz, et al., (2015) found a high resistance against
fluoroquinolones due to their overuse for treatment of urinary tract infections and upper
respiratory infections. The number of therapeutic options are limited in pregnancy and
neonates’ due to the accumulation of tetracycline in developing bones. During pregnancy,
azithromycin 1gram for a single dose is preferred. Erythromycin can also be administered
with a 42% susceptibility rate. (Al-Khadfaji, 2017).
Clinical guidelines and recommendations. Initiating treatment of Ureaplasma spp.
infection is imperative to prevent occurrences of potential future complications. There are
inconsistent partner treatment guidelines found between countries, without any substantial
empirical data to inform treatment decision (Ong, et al., 2017). The recommendations in the
United States for treatment of Ureaplasma is found through the CDC. For treatment of nongonococcal urethritis or cervicitis, the Centers for Disease Control and Prevention currently
recommends azithromycin, 1g orally in a single dose or doxycycline, 100mg twice a day for
7 days (Terris & Kim, 2018). This recommendation reflects all genital pathogens and is not
exclusive to Ureaplasma spp.
Waites and Bronze (2019) states “successful treatment hinges on promptly
considering Mycoplasma and Ureaplasma species as potential etiologic agents, performing
proper diagnostic tests for their detection, and providing appropriate antimicrobial coverage"
(p. 8). Ureaplasma spp. are opportunistic organisms that may be present simultaneously with
other pathogens, such as bacterial vaginosis. Treatment decisions should reflect this.
The literature review supported the investigator’s PICO question of antibiotic
treatment options and provides guidelines on treating both partners for symptomatic genital
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Ureaplasma. With risk factors of untreated Ureaplasma, including infertility in women at 2132%, pregnancy risks, and PID, it is important to consider proper antibiotic treatment
(Tandon, Munne, Chauhan, & Patil, 2019). By providing a quality initiative, supported by
the literature, the project may increase provider knowledge at the obstetric/gynecologic
practice site for the capstone project.
Market Risk Analysis
SWOT Analysis
To perform an analysis of the market where the capstone project was completed, a
SWOT Analysis was conducted identifying the Strengths, Weaknesses, Opportunities, and
Threats (See Appendix D). There were a number of strengths identified for this project,
including evidenced based practice and guidelines as reviewed in the systematic review of
literature. Nucleic Acid Amplification Tests (NAAT) are readily available in the clinical
setting, and there was clinical support from providers for a quality initiative project.
The investigator identified weaknesses to the project as well. One of the hurdles
encountered was the investigator was no longer employed at the site the capstone project was
to take place. This led to early written approval of a letter of intent submitted to the health
care corporation for review. The site is now a midwife only practice; however, they are able
to provide obstetrical and gynecologic care at the capstone site. Another weakness identified
was potential resistance to change provider practice of treatment of genital Ureaplasma. The
final weakness identified was data collection being limited to one area located in the metroDenver area.
The project allowed for recognition and staff development opportunity to providers in
the clinical site by providing an evidenced based literature review and guidelines, as well as
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acknowledging an easily identified microorganism through NAAT collection to prevent
future obstetrical and gynecologic morbidities. This can decrease the overall cost to health
insurance companies and the patient by providing early detection and treatment, rather than
the costliness of such morbidities such as PID.
There were three threats identified to the project. The first threat is the current
unstable state of the corporate run clinic that was dismantled within a 6-week period, laying
off two physicians and 4 nurse practitioners, and closing two of the three locations. This also
led to the second threat of the current office being short-staffed, therefore, all remaining
providers may not be able to attend the QI presentation due to days off and call schedule.
This may result in providers continuing to practice with inconsistent treatment measures.
The final threat was COVID-19, which delayed collection of the data due to the reduction of
work hours for both the biller printing out the patients fitting the ICD-10 parameters, as well
as the clinical mentor collecting the data.
Driving and Restraining Forces
The driving force behind the capstone project was the rate of recurrent vaginal
infections, intermenstrual bleeding, and pelvic pain that was seen when Ureaplasma was
positively identified on NAAT. The investigator began to notice a pattern of antibiotic
treatment of the patient versus treatment of the patient and the partner. Associated cost with
the return office visits was also a driving force for the project. At this time, the PICO
question was formed and the QI was developed in order to increase staff knowledge of
symptoms associated with Ureaplasma, testing method, antibiotic susceptibility, and
guidelines.
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One of the restraining forces noted by the investigator was possible lack of provider
knowledge of providers on Ureaplasma treatment guidelines. This may lead into a second
restraining force of resistance to change their practice, even with evidence supported by the
literature review. A third restraining force was lack of time in the providers schedule for the
investigator to present the findings to the group during a single session. The presentation may
have to take place on the provider’s day off, which the provider may not agree to attend the
presentation.
Needs, Resources and Sustainability
Needs. The need for the capstone project was first identified in the clinic setting by
the investigator and another nurse practitioner within in the clinic, with a combined
experience as advanced nurse practitioners of 50 years. As testing for genital Ureaplasma
became widely available, pathologists from Metropolitan Pathologists would attend “lunch
and learn” sessions educating the available clinicians on the collection process for genital
Ureaplasma, reporting sheets, and treatment options. Not all clinicians attended the sessions,
while other clinics within the practice did not desire a pathologist to discuss any new testing
options. In time, the two experienced nurse practitioners noticed treatment differences
between clinicians as patients returned to the clinic for recurrent vaginitis symptoms. The
investigator began looking into available treatment guidelines, which was reviewed in the
literature review.
Due to the prevalence of recurrent genital Ureaplasma symptoms and inconsistent
antibiotic treatment, there was a need to implement an educational intervention for clinicians
within the practice.
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Resources. The resources needed to complete the project were minimal. NAAT
testing through PCR, including through NuSwab and Thinprep, are available at no cost to the
clinic or patient. Personnel used for the project included the Capstone Chair, clinical mentor,
HCA contract administrator and security officer, and investigator. The clinical mentor
collected data for the project during her time away from work and had agreed to assist in the
project free of cost. The electronic medical record (EMR) system, Electronic Clinical Works,
is already used nationally through the HCA system. See Appendix E for the cost to replicate
the study.
Sustainability. A sustaining force the investigator planned on implementing was an
evidenced-based practice guideline for the chosen clinic based on project findings, as well as
existing guidelines from the CDC. In order to accomplish this, the investigator used a Power
Point Presentation to educate the providers on guidelines and findings. The investigator also
included laboratory testing that was readily available (NAAT testing through ThinPrep and
NuSwab) to the provider that already exists in the clinical setting as well as the appointed
laboratory used (LabCorp).
Feasibility/Risks/Unintended Consequences
Feasibility. The implementation of the evidence-based project was feasible at HCA
Mountain Vista Midwifery due to the former connection the investigator had as an employee
for several years at the mentioned site. The investigator maintained a positive relationship
with the management team, as well as the providers when exiting the practice. The
availability of the existing positive standing between the investigator and mentor and the
resources available, made this capstone project feasible.
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Risks. There was no risk of harm to human subjects or animals with this quality
improvement (QI) project. The project only collected information that was recorded in the
electronic health record and was given to the investigator by the mentor using aggregated
data. The consent was waived, as the waiver will not adversely affect the rights and/or
welfare of the subjects. The intention of this QI project was to explore best practice for
consistency in antibiotic treatment in patients with positive genital Ureaplasma on genital
culture to promote health of the patient.
Unintended Consequences. The investigator did not have control of the antibiotic that
was prescribed to patients by other providers in the clinic. The investigator also had no
control of whether the patient or patient and partner was compliant and completed the course
of antibiotic therapy prescribed. Other unintended consequences are discussed later in this
paper under findings.
Stakeholders and Project Team
The stakeholders that benefited from the capstone project included the health
corporation that owns the clinic used for the project, providers, patients, their partners, and
the community. The investigator discussed the plan via email for this project with the
stakeholders/health corporation (see Appendix F, Letter of Intent) and worked closely with
the HCA contracts coordinator to obtain site approval for conducting the project.
The project team included the Regis University faculty project chair, the Regis
University DNP student (investigator), and the capstone clinical mentor.
Cost-Benefit Analysis
A retrospective data analysis was used, and therefore, data was readily available at no
cost to the investigator. Charts were readily available to the clinical mentor who assisted in
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gathering data for compliance with HIPAA. The clinical mentor agreed to review patient
charts on her time away from the work place.
The cost that was incurred for the patient who is seen in the clinic for symptoms of
vaginitis, pelvic pain, dyspareunia, and intermenstrual bleeding, and/or history of Ureaplasma
was charged a co-payment, which usually ranges from $2.00-$50.00. The insurance is billed
a CPT charge at a 99203 (new patient with a detailed history, detailed exam, and low
complexity decision making) or 99213 (existing patient with a detailed history, detailed
exam, and low complexity decision making). The reimbursement from a 99203 and 99213
visit is $109.46 and $72.70 (E/M University, 2017). The transport media used through
LabCorp was free of charge to the clinic. The cost of running the testing for genital
Ureaplasma and Mycoplasma is $122.75 through LabCorp. The out of pocket cost of oral
doxycycline 100mg twice a day for 7 days is $7.68-$14.17 when using the GoodRx phone
application (2019). For the uninsured patient, the total cost to the patient is estimated at
$203.13 for an existing patient and $239.89 for a new patient.
In comparison, the average cost of treatment for pelvic inflammatory disease per the
CDC (2017) is $3,202. Since PID can lead to future complication, such as an increased risk
of ectopic pregnancy and infertility, the cost of untreated genital Ureaplasma can be an
economic burden to the patient.
Project Objectives
Mission and Vision
The mission was an evidenced based project to determine if there was a relationship
between antibiotic treatment differences and recurrence of symptomatic Ureaplasma. By
determining a relationship between antibiotic treatment of the female patient and their
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partner, it allowed the primary researcher to identify patients at risk and prevent further
disease by proper treatment. The investigator’s vision was to have a standardized testing and
treatment for patients with a positive genital Ureaplasma spp. culture.
Goals
The goal of this project was to determine whether the relationship between treatment
differences and recurrence of symptomatic genital Ureaplasma was statistically significant.
Another goal was to explore the recommendations of evidenced-based guidelines related to
urethritis and cervicitis caused by Ureaplasma.
Process/Outcome Objectives
The focused outcome objective for this project was to perform a retrospective chart
review for patients seen in the clinic from 2018 through 2019, in order to measure rates of
symptomatic recurrence of genital Ureaplasma in the intervention (treating patient and
partner with antibiotic therapy) and comparison groups (treating the patient alone). This time
period was selected to give data for a one-year period, in addition to a three- month time
period for recurring symptoms. The investigator followed a specific project timeline, shown
in Appendix G, to achieve completion of the project.
Logic Model
A logic model template adapted from Zaccagnini & White (2017) was used to outline
the target short-term and long-term goals and benchmarks for the investigator (see Appendix
H). The first step on of the conceptual model, was to establish a close working relationship
with the DNP clinical mentor and the DNP project chair at Regis University. Developing a
relationship helped the investigator identify and implement an achievable outline for the
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project. The Logic Model also helped the investigator determine activities to conduct the
project with expected outputs.
Methodology and Evaluation
QI Project Study Design
The capstone quality improvement initiative required the investigator to use a nonexperimental quantitative study design using a retrospective chart review. Using a
retrospective chart review for the project allowed the investigator to have quick and readily
available access to patient records, allowing less loss of follow up of recurrent symptoms
(Nickson, 2019). Other advantages of using RCR include providing a cost-effective and
efficient means to collect (Gregory & Radovinsky, 2012). Disadvantages of a retrospective
chart review included inconsistent and incomplete or missing entry in the EMR and using a
convenience sample may not be representative of the general population (Gregory &
Radovinsky, 2012)
The independent variables of the project identified were 1) antibiotic treatment of the
patient and partner and 2) antibiotic treatment of the patient alone with doxycycline,
azithromycin, or “other” antibiotic. The dependent variable or outcome was a decrease in the
incidence of symptomatic recurrence as measured by the difference in means between the
two groups (patient treated alone versus treatment of patient and partner). Dependent
variables were identified by 1) test of cure results when both patient or patient and partner are
treated with antibiotics or 2) resolution of symptoms measured by no return clinical visit for
symptoms within a 3-month time period.
Extraneous variables that the researcher encountered was lack of patient follow up for
a test of cure, co-infections, treating provider that is treating the patient and the choice of
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antibiotics, patient compliance in completing the antibiotic regime, and form of
contraception.
Data Collection and Treatment Procedure
The primary investigator followed the steps below when conducting the
retrospective chart review:
1) Obtained approval to conduct QI project from Regis University IRB after submitting QI
Checklist and Summary as well as approval from HCA (for example contracts personnel,
IT security officer).
2) The primary investigator was responsible for overseeing data collection by providing
ICD-10 codes to the clinical mentor to identify patients with positive genital Ureaplasma.
The clinical mentor was the only one that collected data from the clinic patient EHRs.
a. Identified ICD-10 codes of symptomatic signs of genital Ureaplasma in female
patients.
b. Collected NAAT testing results for genital Ureaplasma spp.
c. Identified treatment of patient (comparison) versus treatment of patient and
partner (intervention).
d. Identified patients that returned for recurrent symptoms of genital Ureaplasma in
a three-month time period or returned for a test of cure after treatment.
e. Identified which antibiotic was used for treatment.
3) Measured the difference between patients that were treated with antibiotics alone
versus the treatment of the patient and partner.
4) Shared results of QI project with stakeholders (obstetric/gynecologic providers) after
the DNP project defense.
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Population and Sampling Parameters
The sample population used for the capstone project included a convenience sample
of a total of 128 subjects where only the patient was treated with antibiotics or the patient and
partner were treated with antibiotics between 2018 and 2019. The sampling size was
calculated using the G*Power software (Department of Psychology, 2019) with the alpha of
0.05 and power of 0.80.
The investigator used ICD-10 codes to identify patients that had been seen for
possible genital Ureaplasma. The ICD-10 codes that were used are: N76.1 (chronic vaginitis),
R01.2 (pelvic pain), N89.8 (Other specified non-inflammatory disorders of vagina), N93.9
(abnormal uterine and vaginal bleeding), and N94.1 (dyspareunia) (ICD.codes, 2020).
Inclusion criteria were: the patient will have a positive PCR testing for Ureaplasma species,
regardless of co-infections, as well as antibiotic treatment, including azithromycin,
doxycycline, and clindamycin. Exclusion criteria included subject’s having an IUD in place
and not having a current partner for treatment. The reasoning for the exclusion is to eliminate
the variable of a new partner within the 3-month time frame and the lack of comparison of
patient and partner treatment versus patient treatment only with the same sexual partner. The
reason for excluding patients with IUD’s is antibiotics cannot penetrate non-living
tissue/devices, therefore Ureaplasma can continue to inhabit the IUD device causing
recurrence of Ureaplasma. Pregnant women are considered a vulnerable population;
therefore, they were excluded from the project.
Setting
The setting for the capstone project was a three clinic, corporate owned obstetrics and
gynecology office located in three cities in the metro-Denver area. During the period of time
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that will be used for the retrospective chart review, there were thirteen providers (six
physicians, three midwives, and four nurse practitioners. An estimated 1,500-2,000 patient
visits were documented per month in all three offices.
The site since downsized to a midwife clinic with three full-time and one part-time
certified nurse midwives. Currently, there are approximately 300-400 patient visits per
month. The current location, located in Englewood, Colorado, consist of a main medical
office, as well as a procedure office where ultrasound and colposcopy is performed. The main
office has six exam rooms and two rooms used for fetal monitoring.
Study Instrument: Description, Validity and Reliability
Reliability and validity were essential to validate the project. The data collection tool
consisted of the Hologic Aptima Mycoplasma genitalium Assay. The Hologic website
defines the Aptima Mycoplasma genitalium assay as an in-vitro nucleic acid amplification
test (NAAT) used as the detection of ribosomal RNA (rRNA) from Mycoplasma and
Ureaplasma species (Hologic, 2016). The test is able to categorize the microorganisms into
M. hominis, M.genitalium, Ureaplasma urealyticum, and Ureaplasma parvum. The test
results are automatically interpreted by the Panther system Aptima Mycoplasma genitalium
Assay software. The software does not quantify the amount of the microorganism present,
but provides a qualitative measure (presence of genital Ureaplasma per microscopic field) of
genital Ureaplasma found on the vaginal or endocervical culture. Control testing is run to
establish validity by completion of an assay calibration, which is valid for up to 48 hours. Per
Hologic (2016), “one positive calibrator tube and one negative calibrator tube are run in
duplicate each time a reagent kit is loaded on the Panther system. Software on the Panther
system alerts the operator when a new calibrator set is required” (p. 17).
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The data collection tool utilized in this study was created by the investigator and
content validity was assessed by the clinical mentor. A detailed data dictionary, found in
Appendix I, defines each datum that will be collected from the EMR. This dictionary served
as a guide for the chart reviewer to use when using the data collection tool (see Appendix J).
The investigator used numbers 1-128 to identify participants. The PCR testing, collected
from NuSwab and ThinPrep media was sent to LabCorp for positive identification of
Ureaplasma species. Also included on the data table are descriptions for presenting symptoms
using select ICD-10 codes, treatment of partner.
Protection of Human Subjects
Before seeking approval from the IRB from Regis University, the investigator
completed the Collaborative Institutional Training Initiative (CITI) courses (Certificate #
34972066) to ensure participants safety (see Appendix K). A letter of intent was submitted by
the investigator and was granted approval by HCA Healthcare on March 27, 2020 (see
Appendix L, HCA Approval Email).
The primary investigator was responsible for maintaining integrity of the project and
patient confidentiality. There were minimal to no risk to the patient because the data was
gathered from existing medical records following the treatment of genital Ureaplasma. In
order to maintain patient confidentiality, the clinical mentor collected data by using ICD-10
codes and patient identifiers such as name, date of birth (DOB), address, or medical record
number were not included in the data collection process. The clinical mentor already had
HCA’s permission for remote secure access to the electronic medical records outside of work
hours (see Appendix M, Data Use Agreement). The clinical mentor collected data over a
four-week time period. The de-identified data was delivered to the primary investigator via
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the secure Regis University email system. Once all information was gathered, the investigator
organized the results on a Microsoft Excel spreadsheet.
The results were reported as de-identified, aggregate data. The clinical mentor and the
investigator have been in the medical field over 20 years and stayed within compliance of the
Health Insurance and Portability Accountability Act (U.S. Department of Health and Human
Services, 2015).
The investigator sought approval for the QI project with assistance from the Capstone
Chair. The investigator was granted approval to conduct the project as non-research (QI)
from the IRB on April 16, 2020 (see Appendix N, IRB Net Board Action Email).
Data Collection and Statistical Test
The investigator used percentage change as the descriptive analysis for the Capstone
project. Percentage change is a mathematical calculation determining the percentage
difference between two scores. The statistical tool was chosen to specifically measure the
percentage difference between Group A: Ureaplasma positive patient alone was treated with
antibiotic therapy and Group B: Ureaplasma positive patient and partner was treated with
antibiotic therapy. The investigator also used Kendall’s tau as the inferential statistic.
Kendall’s tau is a nonparametric, inferential test measuring the correlation between two
variables (Polit, 2010).
There were two levels of data used in the project. Nominal data is the lowest form of
measurement and can be divided into categories (Polit, 2010). Identified nominal data were
the antibiotic prescribed to the patient and test of cure findings. The other level of data used
for the project was ordinal data, which classifies variables relative to the dimension of
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interest (Polit, 2010). Ordinal data identified were partner treatment with antibiotics and
recurrence of symptoms.
Project Findings
The investigator asked the clinical mentor to collect data by using a retrospective
chart review from 2018 through 2019 using a convenience sample of 128 subjects that were
seen in the clinical setting with positive genital Ureaplasma cultures.
The results of the data led the investigator to address the PICO statement. In addition,
the investigator unintentionally identified the recurrence of genital Ureaplasma with and
without partner treatment and comparing azithromycin, doxycycline, and clindamycin.
Project Objective
The primary objective identified was to assess the rate of symptomatic recurrence of
genital Ureaplasma in the intervention (treating patient and partner with antibiotic therapy)
and comparison groups (treating the patient alone).
Statistical Data
Pie charts were used to represent the number of cases where the partner was treated
with antibiotic therapy, antibiotic prescribed, and symptoms of recurrence (Figure 1).
The first pie chart represents whether the patient’s partner was treated (n=59, 47%) or
not treated (n=69, 53%) with antibiotics.
The second pie chart identifies the percentage rate of antibiotics prescribed for the
patient. Doxycycline was prescribed the most out of all the antibiotics, where n=116, 91%.
Followed by azithromycin (n=9, 7%). Lastly is clindamycin, where it was prescribed to three
subjects (2%).
The last pie chart shows the rate of patient recurrence of symptomatic genital
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Ureaplasma after initial treatment. Recurrence rate in a three-month period was 46% (n=60).
The rate of lack of symptoms occurred in 54% (n=60) of the subjects identified.
Figure 1
Statistical Pie Charts

All raw data was converted from a “yes/no” format to a numerical format in order to
use SPSS for this project. When running the data “1” equates to “no,” which included the
partner not being treated with an antibiotic and recurrence in a three-month timeframe. The
number “2” identified partner treatment and recurrence of symptoms.
Test of cure (TOC) was labelled as:
0=TOC not done
1=TOC with negative result
2=TOC with positive result
The investigator did collect the data for TOC; however, the investigator did not
analyze data pertaining to this variable as it was not seen as a factor in the recurrence of
symptomatic genital Ureaplasma.
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Results
The interpretation of the table below recognizes the frequency of recurrent symptoms
of the patient. In “1” (partner not treated), 53.9% of patients returned for recurrent symptoms
if their partner was not treated for genital Ureaplasma. In “2,” 46.1% of the patients did not
return in a three-month period of time for recurrent symptoms. Using the percentage change
equation, the difference between the two scores is 14.47% (Table 1).
Table 1
Partner Treatment and Recurrence Rate

Using Kendall’s tau to measure correlation, the investigator found that there was no
statistical difference whether the patient’s partner was or was not treated with antibiotic
therapy and recurrence of symptoms with p<0.05 (Table 2).
Table 2
Kendall’s Tau
Kendall’s Tau (Sig. 2tailed)

Antibiotic

Partner Treated

TOC

Recurrence

Antibiotic

.

.292

.862

.190

Partner Treated

.292

.

.547

.816

TOC

.862

.547

.

.520

Recurrence

.190

.816

.520

.

CONSIDERATIONS OF ANTIBIOTIC TREATMENT

28

Further data was run using SPSS for nominal and ordinal levels of collected.
Unintentional findings of antibiotic effectiveness of patient treatment versus patient and
partner treatment were analyzed as the investigator and statistical mentor used the percentage
change (see Table 3).
Using the percentage change mathematical equation, the investigator found that when
the patient was treated with azithromycin (n=9) and the partner was not treated, there was a
50.07% recurrence rate of symptomatic Ureaplasma. The exact same percentage of the
recurrence rate applies if both the patient and partner were treated with azithromycin,
If the patient was treated with doxycycline (n=116), and the partner was not treated
with antibiotics, the rate of recurrent symptoms was 20.47%. If both the patient and the
partner were treated with doxycycline, the rate of symptomatic recurrence drops to 16.59%
(Table 3).
Only three patients received Clindamycin and all three patients had a symptomatic
recurrence regardless if the partner was treated or not. Comparing the antibiotic treatment, the
results show the antibiotic of choice at this obstetric-gynecological practice was doxycycline
for symptomatic genital Ureaplasma, with azithromycin as a secondary choice. The findings
support the recommendations from the CDC and UpToDate.
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Table 3
Evaluating Partner Treatment, Antibiotic, and Recurrence

Limitations, Recommendations, and Implications
Limitations
Limitations of this study included a small sample size and a single area in Colorado,
therefore the findings cannot be applied to the general population. Another limitation noted
are the number of subjects that were prescribed doxycycline were at a higher rate than
azithromycin and clindamycin. A third limitation identified is the lack of interrater reliability
with the collection tool. Lastly, the project did not include pregnant women or include
contraception measures. In the clinical setting, it was noted that women with IUD’s had
recurrent symptoms of genital Ureaplasma whether the partner was treated or not treated with
antibiotics.
Recommendations
The investigator recommends using a larger sample size to test for statistical
significance of the treatment of the partner for genital Ureaplasma as per the current CDC
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guidelines. The investigator also recommends a follow-up project to assess the use of
doxycycline only to identify recurrence rate with the larger sample size. Lastly, the
investigator recommends a project addressing IUD’s and recurrence of genital Mycoplasma.
Polymer implants have been associated with infections resulting from bacteria and biofilm
adhesion to an implant surface. Ribeiro et al., 2012 noted that once biofilm bacteria inhabit
the implant, there is a high resistance to conventional antibiotics therapy.
Implications
While this study did not generate new phenomenon, the antibiotic findings were
consistent with CDC guidelines. It appears that doxycycline has a higher success rate for
treatment of genital Ureaplasma.
The results showed there was not a statistical improvement of recurrence of genital
Ureaplasma, however; there was improvement of 14.47% between patient partner versus
patient and partner treatment. Therefore, even though not statistically significant,
consideration to clinical significance when looking at percent change can be significant in
terms of cost and quality of life to the patient. When presenting to the stakeholders, the
investigator will recommend a trial study in which both patient and partner are treated with
antibiotic therapy and analyze the results using the percentage differences to identify if
there is a further decrease in recurrence.
Summary
The proposed quality improvement project is specific to three metro-Denver area
outpatient obstetrics and gynecology offices owned by a national corporation. The
investigator explored the use of evidence-based guidelines related to treatment of female
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patients with a positive genital Ureaplasma culture identified by PCR testing, with and
without partner treatment.
The investigator addressed the PICO question for this project by using a retrospective
chart review and a percentage difference for descriptive analysis. Even though the
investigator did not find statistical significance between patient and patient and partner
antibiotic treatment and recurrent Ureaplasma, the investigator observed a possible
relationship between recurrent symptoms and the prescribed antibiotic. Further studies would
be indicated based on the clinical considerations to the patient’s quality of life and partner
treatment for symptomatic genital Ureaplasma. The clinical importance of the study, though
not statistically significant, support the CDC guidelines of patient treatment of genital
Ureaplasma with doxycycline or azithromycin, as well as partner treatment.
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Neuman’s Systems Model

(Flaherty, 2017)
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Lewin’s Theory of Change

Wojciechowski et al, 2016
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Appendix C
Literature Review Example

Article Title and
Journal
Author/Year

Susceptibility and antimicrobial resistance of genital ureaplasma
parvum. Nano Biomedicine and Engineering, 9 (3), 236-241.
Al-Khadfaji, G. K. (2017).

Database and
Keywords
Research Design
Level of Evidence

Database: Ovid. Keywords: Genital and ureaplasma
Quasi-experimental
Level III

Study Aim/Purpose
Population
Studied/Sample
Size/Criteria/ Power

Methods/Study
Appraisal/ Synthesis
Methods

Investigating the antimicrobial susceptibility of Ureaplasma
parvum to determine the best course of antibiotic treatment.
35 samples of Ureaplasma parvum. No criteria or power
identified.
1)Fixed amount of Ureaplasma parvum was cultured in broth
medium in sterile test tubes. 2) Concentrations were numbered
for addition of each antibiotic and stored at 37 Celsius x 48hours
3) Agar medium was then inoculated and stored at 37 Celsius x
24 hours 4) Amount of bacterial growth was then analyzed.

Author Conclusions/
Implications of Key
Findings

80% of Ureaplasma parvum isolates were susceptible to
doxycycline at the highest with 0% susceptible to gentamycin and
azithromycin.
For treatment of Ureaplasma parvum, doxycycline (80%
susceptible), clarithromycin (71.4% susceptible), and
levofloxacin (65.7% susceptible) should be the antibiotics of
choice.

Strengths/ Limitations

Strengths: controlled environment of test tubes and culture
growth. Susceptibility was performed using 6 different
antibiotics. Limitation: Small sample size, no mention of how
collection of Ureaplasma parvum was obtained, and presence of
the growth of bacteria was measured by turbidity only.

Funding Source

None listed

Comments

Erythromycin was recommended for treatment during pregnancy,
which has a 42% susceptibility rate.

Primary Outcome
Measures and Results
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Appendix D
SWOT Analysis
Strengths
•

Evidenced based practice and
guidelines supported by the
systematic review of literature

•

Favorable Nucleic Acid
Amplification Tests (NAAT) readily
available in the clinical setting

•

Weaknesses
•

Investigator is no longer employed
at the site the capstone project

•

Capstone site is now a midwife-only
practice with five practicing
providers

•

Potential resistance to change
provider practice of treatment of
genital Ureaplasma

Clinical support from providers for a
quality initiative project
•

Opportunities
•

Provide evidenced based literature
review and guidelines to existing
providers

•

Providing information of NAAT
collection to identify Ureaplasma

•

Decrease future obstetrical and
gynecologic morbidities caused by
genital Ureaplasma

•

Decrease the overall cost to health
insurance companies and the patient
through early detection

Data collection is limited to one area
located in the metro-Denver area
Threats
•

Unstable state of the corporate run
clinic

•

Remaining five providers may not
be able to attend the QI presentation
resulting in providers continuing to
practice with inconsistent treatment
measures
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Appendix E
Budget and Resources
Items
Investigator Time: $50/hour x
80 hours
Collection time $50/hour x 40
hours
EMR/provider/month
(estimate)
NAAT (Thin prep, 500 count)
G*Power Software (free
download)
Total
*University of Wisconsin-Madison, 2016
Personnel:
• Investigator
• Patients
• Clinical mentor
• Capstone chair
Time:
• Retrospective Chart Review
Equipment:
• EMR
• NAAT

Cost
$0

Cost to Replicate
$4,000

$0

$2,000

$0

$175

$0
$0

$2750*
$0

$0

$8,925
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Appendix F
Letter of Intent
DNP Quality Improvement Project Letter of Intent
To: Laura Collison
From: Shelbie Paul
Subject: DNP Project
Date: December 11, 2019
I am writing to obtain permission to conduct a quality improvement (QI) project in your
facility (Mountain Vista Midwifery) with the purpose of using a retropective chart review
study design to investigate if there is a difference in the incidence of symptomatic recurrence
of genital Ureaplasma in the female patient, when treating the patient and partner as
compared to treating the patient alone with antibiotics. This project will be done to fullfill
requirements for completion of the Doctor of Nursing Practice degree at Regis University,
Denver, CO. The following information will review the study:
This project will employ a Population-Intervention-Comparative-Outcome (PICO)
format for development of the DNP project question to be investigated:
Population: Women with symptomatic genital Ureaplasma
Intervention: Treating patient and partner with antibiotic therapy
Comparative: Treating the patient alone
Outcome: Decrease in the incidence of symptomatic recurrence of genital Ureaplasma
Quality Improvement Project Question: Do women with symptomatic genital
Ureaplasma have a decreased incidence of symptomatic recurrence when both the patient
and the partner are treated with antibiotic therapy than treatment of the patient alone?
Project Significance: Untreated, genital Ureaplasma can lead to pelvic inflammatory
disease, infertility, premature rupture of membranes, preterm delivery, and infection in the
neonate (Verteramo et al., 2013).
The Centers for Disease Control and Prevention (CDC, 2015) recommends treatment with
azithromycin and doxycycline; however, the efficacy of azithromycin is declining. Women
treated for cervicitis, should abstain from intercourse until their partners have completed
treatment with antibiotic therapy.
Findings in this QI project may support the creation of a standard approach based on the
CDC guidelines in managing the care of women with symptomatic Ureaplasma.
Type of Quality Improvement Project Study Design: A retrospective chart review using a
convenience sample
Participant Requirement: None, as the data collected already exists in the chart. While
conducting the retrospective chart review, I will be working with my clinical mentor, Shana
Martin, CNM, in using ICD 10 codes to identify the diagnosis of Ureaplasma, and its
treatment and recurrence.
Risks, Cost, and Benefits:
• Risks: Risks are minimal to none for the participants. The project will use existing data in
the electronic health record. Data collected will be de-identified. I will submit an
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application to the Regis University IRB and HealthOne IRB (if required) prior to
conducting this quality improvement project.
Costs: The cost will be minimal to none to conduct the retrospective chart review.
Benefits: If all providers treat the patient and partner, there may be a decrease in cost to
the insurance company and patient related to long-term issues caused by genital
Ureaplasma pathogens.

Project Goals and Objectives:
The main goal of this project is to explore if there is a difference in the incidence of
symptomatic recurrence of genital Ureaplasma based on two treatment modalities; treating
the patient only or treating the patient and partner with antibiotics.
Objectives:
1. Identify symptoms of vaginitis
2. Identify antibiotic treatment
3. Identify if the patient alone or the patient and partner were treated for Ureaplasma.
4. Measure rates of symptomatic recurrence of genital Ureaplasma in the intervention
and comparison groups
5. After DNP Capstone defense, share results of QI project with leadership at site of
study
Permission is requested to conduct this quality improvement project at Mountain Vista
Midwifery located at 701 E. Hampden Ave. Suite 110 Englewood, CO 80113.
I have included a template for the brief site approval letter that is required on letterhead from
you.
Thank you for your assistance with completing my DNP Quality Improvement Project.
Sincerely,
Shelbie Paul, DNP Student
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Timeline
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Appendix H
Logic Model

Personnel

Constraints
Establish working
relationship with project
chair and clinical
mentor.
Identify
providers that are testing
for Ureaplasma
Treatment regimen

Activities
Staff reporting
positive Ureaplasma
cx
Training providers to
identify patients for
appropriate testing
Collection of
appropriate genital
swabs

Outputs
Test for ureaplasma
species
Identify the
appropriate patient
for testing
Inconsistency of
treatment of patient
and partner vs
patient only

Lab costs to patient
depending on insurance
coverage

Time

IRB approval time

Retrospective study

Time Restraint
of retrospective chart
review

Collecting data

Long term
Develop
consistency of
care within a
HCA Ob/Gyn
practice

Impact
Providers
identifying the
patient on the
first visit that
should be tested
for ureaplasma

Decrease the
incidence of
recurrent
Ureaplasma

Treatment per
CDC guidelines

Decrease cost of
return visits for
patient for
recurrent
symptoms
Not identified

Decreasing the
number of visits
for patients for
recurrent
symptoms
Not identified

Identify
appropriate course
of antibiotic
treatment by CDC
guidelines

Identify antibiotic
used for treatment

Financial

Short term
Identify
appropriate
patient for testing
(pelvic pain,
reoccurrence of
BV, increase in
vaginal discharge,
dyspareunia,
urethritis, history
of infertility)

Lab costs to patient
depending on
insurance coverage

Present evidence
to providers
Cost of antibiotics
for the patient

Time lapse between
positive culture,
calling and treating
patient and partner

Course of
antibiotic
treatment (7 days)

Identifying patient’s
that return to the
office within 3
months with
reoccurring
symptoms
Comparison of
antibiotic treatment
of patient vs
treatment of patient
and partner for
reoccurrence of
ureaplasma and
mycoplasma

Materials

PCR or Thin Prep
transport media

Review reports
received from
laboratory

Prescription for
antibiotics (verbal or
electronically sent to
the pharmacy)

Patient
compliance in
taking full course
of antibiotics

Not identified

Not identified

Equipment

Electronic Health
Records downtime, lack
of internet connectivity
HCA clinic services
(OB/gyn only)

Electronic Health
Records

HER

None

None

None

HCA clinic services

Not identified

Not identified

Not identified

HCA clinic
services

Facilities

HCA approval
Adapted from “The Doctor of Nursing Practice Essentials,” by M. E. Zaccagnini and K. W. White, 2017.
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Appendix I
Data Dictionary
NAME
NAAT testing: NuSwab or
Thinprep (PCR: polymerase
chain reaction)

DESCRIPTION
Positive or negative

Subject

Numeric identification

Test site
Presenting symptoms

N/A
ICD-10 codes

Treatment of partner

Yes or no

Antibiotic prescribed

TOC on follow-up visit

Numeric
1)Azithromycin
2)Doxycycline
3)Other
Positive, negative, not done

Recurrence in 3-month period
(Y/N)

See ICD-10 “Presenting
symtoms”

PCR: polymerase chain reaction)

FORMAT
Nucleic Acid Amplification Test
collected form the endocervical
canal/vaginally.
PCR will be resulted as
“positive” or “negative” and
identify Ureaplasma species.
A number between1-128 will be
assigned to each subject
Healthone clinic services
N76.1 (chronic vaginitis)
R01.2 (pelvic pain)
N89.8 (Other specified noninflammatory disorders of
vagina)
N93.9 (abnormal uterine and
vaginal bleeding)
N94.1 (dyspareunia)
Telephone encounters to patients
will need to be looked at to see if
the partner was treated or not
Type of antibiotic used will be
identified

NAAT test results after
completion of antibiotic therapy
(8-21 days)
NAAT test with positive results
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Appendix J
Collection Instrument for Retrospective Chart Review
Sample
Number

1
2

ICD-10 Visit
Code
Associated
with
Ureaplasma

NAAT Test
Results

Name of
Antibiotic
Prescribed

Partner
Treated
(Y/N)

TOC
(positive,
negative,
or not
done)

Recurrence
in 3 Month
Period
(Y/N)
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CITI Training Certificate
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HCA Approval Email
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Appendix M
Data Use Agreement

DATA USE AGREEMENT
This Agreement is entered into as of March 26, 2020 (the "Effective Date"), by and
between Mountain Vista Midwifery ("Practice") and Shelbie Paul ("User"). User is pursuing a
Doctor of Nursing Practice degree at Regis University and desires to access certain patientrelated data of Practice for research required in order to complete such degree. In connection
therewith, the parties wish to exchange a limited data set as permitted by the HIPAA Privacy
Rules (45 CFR Part 160 and Part 164, Subparts A and E) for research purposes in accordance
with the terms and conditions set forth in this Agreement. In consideration of the mutual
promises hereinafter recited, the parties hereto agree as follows:
1. Definitions. Limited Data Set shall have the same meaning as the term "limited data set" in
45 C.F.R. §164.512(e)(2), as amended from time to time. Any remaining terms used, but
not otherwise dermed, in this Agreement, shall have the same meaning as those terms in
the HIPAA Privacy Rule, as amended from time to time.
2. Permitted Uses and Disclosures. Practice will provide data as described on Exhibit A
("Data") to User. The Data will constitute a Limited Data Set. User agrees to only use the
Data for the purposes of the research described on Exhibit A consistent with the HIPAA
Privacy Rule. User shall not disclose the Data to any third party unless agreed in writing in
advance by Practice or unless the Data has been further de-identified so that it complies with
the de-identification safe harbor set forth at 45 CFR §164.514(b), which among other things
requires that any dates or portions of dates (other than year) be removed, including dates of
service.
3. Other Obligations. User will
a. only use and disclose the Data as permitted by this Agreement or as Required By
Law;
b. use appropriate safeguards to prevent use or disclosure of the Data other than as
provided for by this Agreement;
c. report to Practice in writing immediately any use or disclosure of the Data not
provided for by this Agreement of which User becomes aware;
d. ensure that any Subcontractors or agents to whom User provides the Data agree to
the same restrictions and conditions that apply to User with respect to such
information; and
e. not identify or attempt to identify the Data nor contact or attempt to contact the
individuals who are the subject of the Data.
4. Term. This Agreement shall be effective as of the Effective Date and remain in effect until
terminated by either party or one year from the Effective Date, whichever is earlier. Either
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party may terminate this Agreement upon thirty (30) days' written notice to the other party.
Upon termination of this Agreement, User shall destroy the Data if feasible. User's
obligations set forth in Sections 2 through 3 shall survive any termination of this
Agreement for so long as User maintains any of the Data.
5. Notice. All notices and other communications required or permitted to be given shall be
made in writing and shall be considered given and received when deposited in the United
States mail, postage prepaid, return receipt requested and addressed as set forth below or
at such other address such party shall have specified by notice given in accordance with
the provisions of this Section:
If to PRACTICE, to:

If to USER, to:

Mountain Vista Midwifery
701 E. Hampden Ave,
Suite 110 Englewood, CO
80113
Attn: Shana Martin

6. Confidentiality. User acknowledges that information regarding Practice's business
operations, including, but not limited to, procedures, programs, formularies and
reimbursement schedules are proprietary and confidential, and agrees to hold such
information in strict confidence and not to disclose or make available such information to
any third party, except as required by law. This provision shall survive termination of this
Agreement.

7. Miscellaneous. None of the provisions of this Agreement are intended to create any
relationship between the parties other than that of independent entities contracting with each
other solely for the purpose of effecting the provisions of this Agreement. The parties agree to
amend this Agreement as necessary to comply with the HIPAA Privacy Rule and other
applicable law. This Agreement constitutes the entire written agreement of the parties with
respect to the subject matter of this Agreement and supersedes any prior written agreements
of the parties regarding the subject matter of this Agreement. Any ambiguity in this Agreement
shall be resolved to permit Practice to comply with the HIPAA Privacy Rule. Nothing in this
Agreement shall confer upon any person other than the parties and their respective successors
or assigns, any rights, remedies, obligations, or liabilities, whatsoever.
IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
and year first above written.
USER:
BY:
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PRACTICE:
By:
William Smitham
Title:

Vice President
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EXHIBIT A
The Data consists of the following:
• ICD-10 Visit Code
• results of culture
• antibiotic prescribed
• partner treated (yes/no)
• TOC/recurrence in 3 month period
Practice will collect data that will constitute a Limited Data Set from its records and
provide the Data to User. The Data is provided for the following research project which
involves collecting data from medical charts on a retrospective basis. User certifies that
the description of the research project set forth below is accurate and complete.
This project will employ a Population-Intervention-Comparative-Outcome (PICO) format
for development of the doctor of nurse practice project question to be investigated:
Population: Women with symptomatic genital Ureaplasma
Intervention: Treating patient and partner with antibiotic therapy
Comparative: Treating the patient alone
Outcome: Decrease the incidence of symptomatic recurrence of
genital Ureaplasma
Quality Improvement Project Question: Do women with symptomatic genital
Ureaplasma have a decreased incidence of symptomatic recurrence when both the
patient and the partner are treated with antibiotic therapy than treatment of the
patient alone?
Project Title: Considerations of antibiotic treatment for genital Ureaplasma.
Project Significance: Untreated, genital Ureaplasma can lead to pelvic
inflammatory disease, infertility, premature rupture of membranes, preterm
delivery, and infection in the neonate.
Type of Quality Improvement Project Study Design: Retrospective
Participant Requirement: None. User will receive Data from Practice.
Risks, Cost, and Benefits: If all providers treat the patient and partner, there will
be a decrease in cost to the insurance company and patient related to long-term
issues caused by genital Ureaplasma pathogens.
Project Goals and Objectives: The main goal of this project is to apply standard of
care to women with symptomatic Ureaplasma.
Objectives:

3
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1. Identify symptoms of genital Ureaplasma species.
2. Identify antibiotic treatment.
3. Identify if the patient alone or the patient and partner were treated
for Ureaplasma.
4. Prevent recurrence of genital Ureaplasma with proper antibiotic treatment.
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